Cure My Disease

Don't miss your cure!

 Log in / Sign up

Supercharged immune cells take on childhood cancers

NCT ID NCT04715191

Recruiting now Disease control Sponsor: Baylor College of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new immunotherapy called CARE T cells in children and young adults with solid tumors that have returned or not responded to standard treatment. The cells are taken from the patient, genetically modified to recognize a protein (GPC3) found on many solid tumors, and given extra signals (IL15 and IL21) to help them survive and fight longer. The main goals are to find a safe dose and see if the cells can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CARE T cells (genetically modified immune cells with GPC3-CAR, IL15, and IL21)

What this could lead to

If it works, this could point toward a new treatment option for children with hard-to-treat solid tumors like liver cancer or rhabdomyosarcoma.

What could go wrong

This is a very early (Phase 1) trial with only 24 participants, so it is too soon to know if the cells are effective. There are also risks of serious side effects, including cytokine release syndrome and nerve problems.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Endodermal Sinus Tumor liposarcoma liver cancer Liver Neoplasms rhabdoid tumor rhabdomyosarcoma Wilms tumor yolk sac tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIPOSARCOMA LIVER CANCER MALIGNANT RHABDOID TUMOR RHABDOMYOSARCOMA WILMS TUMOR YOLK SAC TUMOR

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Texas Children's Hospital

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••